<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="iso-abbrev">An Bras Dermatol</journal-id>
      <journal-id journal-id-type="publisher-id">abd</journal-id>
      <journal-title-group>
        <journal-title>Anais Brasileiros de Dermatologia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0365-0596</issn>
      <issn pub-type="epub">1806-4841</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Dermatologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">27828653</article-id>
      <article-id pub-id-type="pmc">5087238</article-id>
      <article-id pub-id-type="doi">10.1590/abd1806-4841.20164449</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Syndrome in Question</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Syndrome in question: antisynthetase syndrome (anti-PL-7)<xref ref-type="fn" rid="fn1">*</xref></article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Esposito</surname>
            <given-names>Ana Cl&#xE1;udia Cavalcante</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Gige</surname>
            <given-names>Tatiana Cristina</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miot</surname>
            <given-names>H&#xE9;lio Amante</given-names>
          </name>
          <xref ref-type="aff" rid="aff1">1</xref>
          <xref ref-type="corresp" rid="c1"/>
        </contrib>
        <aff id="aff1"><label>1</label>Universidade Estadual Paulista "J&#xFA;lio de
Mesquita Filho" (Unesp), Botucatu, SP, Brazil</aff>
      </contrib-group>
      <author-notes>
        <corresp id="c1">Mailing address: H&#xE9;lio Amante Miot, Departamento de
Dermatologia e Radioterapia, Faculdade de Medicina de Botucatu Unesp, 18618-000
Botucatu, SP. E-mail: <email>heliomiot@fmb.unesp.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Sep-Oct</season>
        <year>2016</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Sep-Oct</season>
        <year>2016</year>
      </pub-date>
      <volume>91</volume>
      <issue>5</issue>
      <fpage>683</fpage>
      <lpage>685</lpage>
      <history>
        <date date-type="received">
          <day>08</day>
          <month>2</month>
          <year>2015</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>4</month>
          <year>2015</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9;2016 by Anais Brasileiros de
Dermatologia</copyright-statement>
        <copyright-year>2016</copyright-year>
        <copyright-holder>Anais Brasileiros de Dermatologia</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution Non-Commercial License which permits
unrestricted non-commercial use, distribution, and reproduction in any
medium provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Antisynthetase syndrome is a rare autoimmune disease characterized by
interstitial lung disease and/or inflammatory myositis, with positive
antisynthetase antibodies (anti-Jo-1, anti-PL-7, anti-PL-12, ZO, OJ, anti-KE or
KS). Other symptoms described include: non-erosive arthritis, fever, Raynaud's
phenomenon, and "mechanic's hands." The first therapeutic option is
corticotherapy, followed by other immunosuppressants. The prognosis of the
disease is quite limited when compared to other inflammatory myopathies with
negative antisynthetase antibodies.</p>
      </abstract>
      <kwd-group>
        <kwd>Amino Acyl-tRNA Synthetases</kwd>
        <kwd>Interstitial Lung Disease</kwd>
        <kwd>Myositis</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>CASE REPORT</title>
      <p>A woman patient, 41 years of age, presented a dry cough and dyspnea upon moderate
exertion, which has become progressively worse over the past four years. Six months
ago, the patient presented proximal muscle weakness and wrist arthralgia. She sought
out the Dermatology department due to a peeling of the edges of the fingers, without
pruritus; periungual erythema; changes in nails and fingers (<xref ref-type="fig" rid="f1">Figure 1</xref>). Physical examination identified a crackling sound in
the lungs. On the hands, one could observe Raynaud phenomenon, peeling, and marginal
hyperqueratosis ("mechanic's hands"); longitundinal hypercurvature of the nail
plate; paronychia; reduction in the volume of finger tissue (digital pulp), with no
ulcerations, sclerodactyly or punctiform scars. Capillaroscopy showed folding,
ischemic areas, and dilated flaps, as well as the absence of heliotrope. Laboratory
exams included FAN 1:160 (speckled) and positive anti-PL-7. Other antibodies
included antisynthetase, antinuclear, anti-Scl-70, ANCA, and latex proved to be
normal. Biochemical exams &#x2013; VHS 122mm/h; Creatine phosphokinase 2759U/l
(reference&lt;135U/l). Electroneuromyography showed a myopathic pattern. Computed
tomography of the thorax showed interstitial lung disease (ILD) with ground-glass
opacity (<xref ref-type="fig" rid="f2">Figure 2</xref>); spirometry disclosed a
restrictive pattern, with no response to the bronchodilator, and the esophagogram
was normal.</p>
      <p>
        <fig id="f1" orientation="portrait" position="float">
          <label>Figure 1</label>
          <caption>
            <p><bold>A.</bold> Periungual erythema, longitudinal hypercurvature of the
ungual lamina and marginal hyperkeratosis of the first finger.
<bold>B.</bold> Detail of the nail hypercurvature (digital
clubbing), retraction of digital pulp, and marginal peeling of the
second finger.(mechanic's hand)</p>
          </caption>
          <graphic xlink:href="abd-91-05-0683-g01"/>
        </fig>
      </p>
      <p>
        <fig id="f2" orientation="portrait" position="float">
          <label>Figure 2</label>
          <caption>
            <p>Computed tomography (high resolution) of the thorax. Fibrosing
interstitial pneumonia with a reticular pattern with areas of
ground-glass alveolar opacity and thickness of the septa (inter and
intralobuar) with traction bronchiectasis, predominantly in the lower
basal regions</p>
          </caption>
          <graphic xlink:href="abd-91-05-0683-g02"/>
        </fig>
      </p>
    </sec>
    <sec sec-type="discussion">
      <title>DISCUSSION</title>
      <p>Antisynthetase Syndrome (ASS), described by Marguerie (1990), represents a rare group
of autoimmune diseases that mainly affect women (2:1) between 30 and 50 years of age
and present autoantibodies geared toward the Amino Acyl-tRNA Synthetases enzymatic
complex, which catalyzes the connection of an amino acid to the RNAt protein
synthesis.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r5" ref-type="bibr">5</xref></sup></p>
      <p>The diagnostic criteria of ASS are available in <xref ref-type="table" rid="t1">chart
1</xref>.<sup><xref rid="r3" ref-type="bibr">3</xref></sup> The most common
clinical manifestations of ASS include: inflammatory myositis (&gt;90%),
Interstitial Lung Disease (ILD) (60%), non-erosive arthritis (50%), Raynaud
phenomenon (40%), "mechanic's hand" (30%), and fever (20%).<sup><xref rid="r6" ref-type="bibr">6</xref></sup> The main differential diagnoses
include progressive systemic sclerosis, dermatomyositis/polymyositis, and overlap
syndromes.</p>
      <table-wrap id="t1" orientation="portrait" position="float">
        <label>Chart 1</label>
        <caption>
          <p>Criteria proposed for the diagnosis of antisynthetase syndrome<sup><xref rid="r3" ref-type="bibr">3</xref></sup></p>
        </caption>
        <table frame="box" rules="groups">
          <colgroup span="1">
            <col width="100%" span="1"/>
          </colgroup>
          <thead>
            <tr>
              <th align="left" rowspan="1" colspan="1">Diagnosis: Presence of one antisynthetase antibody plus
two <italic>major</italic> criteria or one higher criterion and two
<italic>minor</italic> criteria.</th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td align="left" rowspan="1" colspan="1">
                <bold>
                  <italic>Major criteria:</italic>
                </bold>
              </td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">1. Interstitial lung disease (not explained by
environmental, occupational, medication exposure, and not related to
any other base disease)</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2. Polymyositis or dermatomyositis according to
criteria set forth by Bohan &amp; Peter</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">
                <bold>
                  <italic>Minor criteria:</italic>
                </bold>
              </td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">1. Arthritis</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">2. Raynaud phenomenon</td>
            </tr>
            <tr>
              <td align="left" rowspan="1" colspan="1">3. Mechanic's hand</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
      <p>The autoantibodies involved in the disease (in order of frequency) and the amino
acids that are targets of RNAt-synthetase are: anti-Jo1 (histidine), anti-PL-12
(alanine), anti-PL-7 (threonine), anti-OJ (isoleucine), anti-KS (asparagine),
anti-EJ (glycine), and anti-ZO (phenylalanine). The phenotype of the disease varies
according to the expressed autoantibody.<sup><xref rid="r7" ref-type="bibr">7</xref></sup> Myopathy occurs more often in patients with anti-Jo-1 or
anti-PL-7; anti-Jo-1 is related to the more extreme cases of arthritis and
"mechanic's hand", while anti-PL-7 is associated with the presence of heliotrope;
anti-PL-12 with the higher rates of Raynaud phenomenon; and anti-PL-12, anti-KS, and
anti-OJ with cases of isolated ILD.<sup><xref rid="r8" ref-type="bibr">8</xref></sup></p>
      <p>To date, no randomized studies have evaluated the therapeutic effectiveness of
ASS.<sup><xref rid="r7" ref-type="bibr">7</xref></sup> The treatment of
choice is prednisone at an initial dose of 1mg/Kg/day. Other possibilities described
include: tacrolimus, mycophenolate mofetil, immunoglobin, azathioprine,
methotrexate, cyclophosphamide, and cyclosporine.<sup><xref rid="r7" ref-type="bibr">7</xref></sup> Rituximab was reported to be efficient in the treatment of
refractory myositis, but did not influence the evolution of ILD or the loss of
pulmonary function.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r9" ref-type="bibr">9</xref></sup></p>
      <p>The prognosis of ASS is quite limited when compared to other inflammatory myopathies
without antisynthetase antibodies, which results mainly from greater ILD resistance
to corticotherapy, evolving into the need for a lung transplant.<sup><xref rid="r1" ref-type="bibr">1</xref>,<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r10" ref-type="bibr">10</xref></sup></p>
      <p>Our patient was submitted to oral corticotherapy associated with pulse therapy using
cyclophosphamide and, later, with mycophenolate mofetil and rituximab, without, to
date, fully controlling the lung disease.</p>
      <p>Dermatologists must pay attention to myopathic and/or lung conditions that present
the Raynaud phenomenon, nail dystrophy, repeated periungual/paronychia erythema,
atrophy of the digital pulp, and "mechanic's hand" peeling, in an attempt to
collaborate with an early diagnosis of the disease with a limited prognosis</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn fn-type="COI-statement">
        <p>Conflict of Interest: None</p>
      </fn>
      <fn fn-type="supported-by">
        <p>Financial Support: None</p>
      </fn>
      <fn fn-type="other" id="fn1">
        <label>*</label>
        <p>Work conducted in the Department of Dermatology and Radiology of Universidade
Estadual Paulista "J&#xFA;lio de Mesquita Filho" (Unesp) &#x2013; Botucatu Campus,
Botucatu, SP, Brazil.</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>REFERENCES</title>
      <ref id="r1">
        <label>1</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Love</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Leff</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Fraser</surname>
              <given-names>DD</given-names>
            </name>
            <name>
              <surname>Targoff</surname>
              <given-names>IN</given-names>
            </name>
            <name>
              <surname>Dalakas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Plotz</surname>
              <given-names>PH</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A new approach to the classification of idiopathic inflammatory
myopathy myositis-specific autoantibodies define useful homogeneous patient
groups</article-title>
          <source>Medicine (Baltimore)</source>
          <year>1991</year>
          <volume>70</volume>
          <fpage>360</fpage>
          <lpage>374</lpage>
          <pub-id pub-id-type="pmid">1659647</pub-id>
        </element-citation>
      </ref>
      <ref id="r2">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Marguerie</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Bunn</surname>
              <given-names>CC</given-names>
            </name>
            <name>
              <surname>Beynon</surname>
              <given-names>HL</given-names>
            </name>
            <name>
              <surname>Bernstein</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Hughes</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>So</surname>
              <given-names>AK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Polymyositis, pulmonary fibrosis and autoantibodies to
aminoacyl-tRNA synthetase enzymes</article-title>
          <source>Q J Med</source>
          <year>1990</year>
          <volume>77</volume>
          <fpage>1019</fpage>
          <lpage>1038</lpage>
          <pub-id pub-id-type="pmid">2267280</pub-id>
        </element-citation>
      </ref>
      <ref id="r3">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Solomon</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Swigris</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Brow</surname>
              <given-names>KK</given-names>
            </name>
          </person-group>
          <article-title>Doen&#xE7;a pulmonar intersticial relacionada a miosite e a
s&#xED;ndrome antissintetase</article-title>
          <source>J Bras Pneumol</source>
          <year>2011</year>
          <volume>37</volume>
          <fpage>100</fpage>
          <lpage>109</lpage>
          <pub-id pub-id-type="pmid">21390438</pub-id>
        </element-citation>
      </ref>
      <ref id="r4">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ortigosa</surname>
              <given-names>LCM</given-names>
            </name>
            <name>
              <surname>Reis</surname>
              <given-names>VMS</given-names>
            </name>
          </person-group>
          <article-title>Dermatomiosite</article-title>
          <source>An Bras Dermatol</source>
          <year>2008</year>
          <volume>83</volume>
          <fpage>247</fpage>
          <lpage>259</lpage>
        </element-citation>
      </ref>
      <ref id="r5">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Swigris</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>du Bois</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Lynch</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Downey</surname>
              <given-names>GP</given-names>
            </name>
            <name>
              <surname>Cosgrove</surname>
              <given-names>GP</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients
presenting with idiopathic interstitial pneumonia</article-title>
          <source>Respir Med</source>
          <year>2009</year>
          <volume>103</volume>
          <fpage>1719</fpage>
          <lpage>1724</lpage>
          <pub-id pub-id-type="pmid">19497723</pub-id>
        </element-citation>
      </ref>
      <ref id="r6">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Foris</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Kovacs</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Matucci-Cerinic</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Olschewski</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>PL-7 positive antisynthetase syndrome and pulmonary
hypertension</article-title>
          <source>J Rheumatol</source>
          <year>2013</year>
          <volume>40</volume>
          <fpage>1777</fpage>
          <lpage>1779</lpage>
          <pub-id pub-id-type="pmid">24085762</pub-id>
        </element-citation>
      </ref>
      <ref id="r7">
        <label>7</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hallowell</surname>
              <given-names>RW</given-names>
            </name>
            <name>
              <surname>Danoff</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Interstitial lung disease associated with the idiopathic
inflammatory myopathies and the antisynthetase syndrome: recent
advances</article-title>
          <source>Curr Opin Rheumatol</source>
          <year>2014</year>
          <volume>26</volume>
          <fpage>684</fpage>
          <lpage>689</lpage>
          <pub-id pub-id-type="pmid">25203119</pub-id>
        </element-citation>
      </ref>
      <ref id="r8">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dugar</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Limaye</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Blumbergs</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Roberts-Thomson</surname>
              <given-names>PJ</given-names>
            </name>
          </person-group>
          <article-title>Clinical heterogeneity and prognostic features of South
Australian patients with antisynthetase autoantibodies</article-title>
          <source>Intern Med J</source>
          <year>2011</year>
          <volume>41</volume>
          <fpage>674</fpage>
          <lpage>679</lpage>
          <pub-id pub-id-type="pmid">20059602</pub-id>
        </element-citation>
      </ref>
      <ref id="r9">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nalotto</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Iaccarino</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Gatto</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Borella</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Domenighetti</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rituximab in refractory idiopathic inflammatory myopathies and
antisynthetase syndrome: personal experience and review of the
literature</article-title>
          <source>Immunol Res</source>
          <year>2013</year>
          <volume>56</volume>
          <fpage>362</fpage>
          <lpage>370</lpage>
          <pub-id pub-id-type="pmid">23572427</pub-id>
        </element-citation>
      </ref>
      <ref id="r10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Behr</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ryu</surname>
              <given-names>JH</given-names>
            </name>
          </person-group>
          <article-title>Pulmonary hypertension in interstitial lung
disease</article-title>
          <source>Eur Respir J</source>
          <year>2008</year>
          <volume>31</volume>
          <fpage>1357</fpage>
          <lpage>1367</lpage>
          <pub-id pub-id-type="pmid">18515559</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
